Core Viewpoint - Rosen Law Firm is reminding purchasers of Reckitt Benckiser Group PLC American Depositary Shares (ADSs) of a class action lawsuit with a lead plaintiff deadline of August 4, 2025 [1] Group 1: Class Action Details - The class period for the lawsuit is from January 13, 2021, to July 28, 2024, during which investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][5] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [4] Group 2: Allegations Against Reckitt - The lawsuit alleges that Reckitt failed to warn investors that preterm infants were at an increased risk of developing necrotizing enterocolitis (NEC) from consuming its cow's milk-based formula, Enfamil [5] - It is claimed that Reckitt did not disclose the potential impact on sales of Enfamil and the company's exposure to legal claims, leading to materially false and misleading statements about its business and operations [5]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Reckitt Benckiser Group plc regarding a class action lawsuit related to misleading statements about the company's cow's milk-based formula, Enfamil, which allegedly increased the risk of NEC in preterm infants [1][3]. Group 1: Class Action Details - The class period for the lawsuit is from January 13, 2021, to July 28, 2024 [3]. - Allegations include that Reckitt failed to disclose the increased risk of NEC for preterm infants consuming Enfamil, the impact on sales, and exposure to legal claims, leading to materially false and misleading statements about the company's business and prospects [3]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by the deadline of August 4, 2025, to potentially become lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - A class action lawsuit has been filed against Reckitt Benckiser Group PLC for alleged violations of federal securities laws related to misleading statements about the company's products and their safety [1][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased Reckitt securities between January 13, 2021, and July 28, 2024, inclusive [2]. - The complaint alleges that Reckitt's officers made materially false and misleading statements regarding the safety of its cow's milk-based formula, Enfamil, particularly concerning the risk of necrotizing enterocolitis (NEC) in preterm infants [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Reckitt have until August 4, 2025, to request to be appointed as lead plaintiff in the case [4]. - Participation in any recovery does not require serving as lead plaintiff [4]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorneys' fees if successful [5]. - The firm has a history of recovering hundreds of millions of dollars for investors in securities fraud class actions [6].

Group 1 - The Rosen Law Firm is reminding purchasers of American Depositary Shares (ADSs) of Reckitt Benckiser Group PLC about the lead plaintiff deadline of August 4, 2025, for a class action lawsuit [1] - Investors who purchased Reckitt ADSs may be entitled to compensation through a contingency fee arrangement, meaning no out-of-pocket fees or costs [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6] Group 2 - The lawsuit alleges that during the class period, Reckitt failed to warn investors that preterm infants were at increased risk of developing necrotizing enterocolitis (NEC) from consuming its Enfamil formula, which misled investors about the company's business prospects [5]

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Reckitt Benckiser Group PLC American Depository Shares (ADSs) between January 13, 2021, and July 28, 2024, alleging that the company misled investors regarding the safety of its Enfamil baby formula [1][2]. Allegations - The lawsuit claims that Reckitt failed to inform investors and consumers about the increased risk of necrotizing enterocolitis (NEC) in preterm infants consuming its cow's milk-based formula, Enfamil, and the potential negative impact on sales and legal exposure [2]. - A jury in Illinois awarded $60 million in a case against Mead Johnson, finding negligence related to the same NEC risk, which led to a significant drop in Reckitt's ADS price [3]. - Following a similar case in Missouri, where Abbott Laboratories was found liable for NEC, Reckitt's ADS price also experienced a notable decline [4]. Next Steps - Shareholders interested in participating in the class action must file a motion for lead plaintiff by August 4, 2025, with the option to remain an absent class member if they choose not to take action [5].

Core Viewpoint - A class action securities lawsuit has been filed against Reckitt Benckiser Group plc, alleging securities fraud that negatively impacted investors between January 13, 2021, and July 28, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Reckitt Benckiser's cow's milk-based formula, Enfamil, posed an increased risk of NEC (necrotizing enterocolitis) in preterm infants, which was not disclosed [2]. - It is alleged that the company made false statements regarding its business operations and sales prospects, which were materially misleading [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until August 4, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action lawsuit has been filed against Reckitt Benckiser Group plc for allegedly making false and misleading statements regarding the safety of its Enfamil formula, particularly concerning the risk of necrotizing enterocolitis in preterm infants [4]. Group 1: Lawsuit Details - The lawsuit is based on violations of the Securities Exchange Act of 1934, specifically §§10(b) and 20(a), and Rule 10b-5 [1]. - Investors who purchased Reckitt's securities between January 13, 2021, and July 28, 2024, are encouraged to participate in the class action [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against the Company - The complaint alleges that Reckitt failed to disclose the increased risk of necrotizing enterocolitis (NEC) associated with its Enfamil formula for preterm infants [4]. - The company is accused of misleading investors about its exposure to legal claims related to NEC, resulting in materially false public statements throughout the class period [4]. - As a result of the revelations, investors reportedly suffered damages when the truth about Reckitt's practices became known [4].

Core Viewpoint - A class action lawsuit has been filed against Reckitt Benckiser Group plc for allegedly misleading investors regarding the risks associated with its cow's milk-based formula, Enfamil, during the Class Period from January 13, 2021, to July 28, 2024 [1][4]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of New York on behalf of all individuals and entities who purchased Reckitt securities during the specified Class Period [1]. - Investors have until August 4, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations Against Reckitt - The class action alleges that Reckitt made misleading statements and omissions regarding its business, financial condition, and prospects [4]. - Specifically, it is claimed that Reckitt failed to warn investors that preterm infants consuming its Enfamil formula were at an increased risk of developing necrotizing enterocolitis (NEC) [4]. - The lawsuit also asserts that Reckitt did not disclose the potential impact on sales of Enfamil and the company's exposure to legal claims [4]. Group 3: Industry Context - Reckitt, a UK-based global consumer goods company, is facing over 500 state and federal products liability lawsuits related to its formula and that of its competitor, Abbott Laboratories [3].

Core Viewpoint - A class action lawsuit has been filed against Reckitt Benckiser Group PLC on behalf of purchasers of American Depositary Shares (ADSs) during the period from January 13, 2021, to July 28, 2024, due to alleged misleading statements regarding the safety of its cow's milk-based formula, Enfamil, for preterm infants [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Reckitt failed to inform investors that preterm infants consuming Enfamil were at an increased risk of developing necrotizing enterocolitis (NEC) [5]. - It is alleged that Reckitt's positive statements about its business and operations were materially false and misleading, lacking a reasonable basis during the class period [5]. - Investors reportedly suffered damages when the true details about the risks associated with Enfamil became public [5]. Group 2: Legal Representation - The Rosen Law Firm is representing the investors and encourages potential class members to select qualified counsel with a successful track record in securities class actions [4]. - Investors who purchased Reckitt ADSs may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the court by August 4, 2025, to represent other class members in the litigation [1][3].

Core Viewpoint - A class action lawsuit has been filed against Reckitt Benckiser Group Plc, alleging securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - The lawsuit involves allegations against Reckitt and certain officers and directors for engaging in securities fraud or other unlawful business practices [2]. - Investors have until August 4, 2025, to request to be appointed as Lead Plaintiff if they purchased Reckitt securities during the Class Period [2]. Group 2: Financial Impact - On March 15, 2024, Reckitt's American Depositary Share (ADS) price fell by $1.87, nearly 14%, closing at $11.44 following a $60 million verdict against its Mead Johnson subsidiary for negligence related to infant formula [3][4]. - On July 29, 2024, after a similar lawsuit against Abbott Laboratories, Reckitt's ADS price dropped by $1.02, nearly 9%, closing at $10.64 [4]. Group 3: Company Background - Pomerantz LLP, the firm handling the lawsuit, is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud [5].